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Bone is one of the most common sites of prostate cancer metas-
tases. In approximately 95% of cases the cancer promotes new
bone formation, resulting in osteoblastic lesions (Sharp and
McDonald, 1942; Koutsilieris, 1993). Infiltrating prostate cancer
cells are believed to cause a sclerotic reaction and impaired miner-
alization (Charbon et al, 1983). The remaining 5% of bone metas-
tases are a mix of osteoblastic and osteolytic lesions which are
usually associated with the terminal stages of the disease. The
causes for the propensity of prostate cancer to grow in bone and
form osteoblastic lesions remain unresolved.
Previous investigations of osteoblastic lesions have focused on
the prostatic cancer cell effect on osteoblasts and the identification
of mitogenic growth factors produced. Several peptides including
an amino-terminal fragment of urokinase from human prostate
cancer PC-3 cells were identified as the osteoblastic factor
(Rabbani et al, 1990). Increased osteoblast proliferation has been
described to result in the inhibition of differentiation, collagen
synthesis and mineralization (Martinez et al, 1996; Santibanez
et al, 1996). Since normal bone remodelling requires the balanced
activity of osteoclasts in resorbing and osteoblasts in building the
bone, altered function of either could affect bone remodelling. To
investigate progressive bone destruction in prostate cancer it is
necessary to understand the biology of osteoclasts in the patho-
genic process. In this regard we have examined endothelin-1 (ET-
1), which may have a potential role in bone metabolism. ET-1 is an
ejaculate peptide with 21 amino-acid residues (Casey et al, 1992).
ET-1 is produced by a variety of tissues including endothelial cells
(Yanagisawa, 1994) and prostate cancer cells (Nelson et al, 1995).
ET-1 has been proposed to contribute to the osteoblastic response.
This includes the modulation of the mRNA expression of osteo-
pontin and osteocalcin which are phenotype-related gene products
of osteoblasts (Shioide and Noda, 1993) and the stimulation
of new bone formation in a mouse model (Nelson et al, 1999).
Although ET-1 from bone marrow was previously suggested as an
important regulator for osteoclasts, that activity was not linked to
prostate cancer cells. In this report we have investigated the osteo-
clast-inhibiting activity of ET-1 derived from prostate cancer cells.
There is evidence that ET-1 is a major factor responsible for the
prostate cancer cell-mediated inhibition of osteoclastic bone
resorption. Additionally, ET-1 level in prostate cancer cells is
enhanced by bone or PSA stimulation.
MATERIAL AND METHODS
Cell lines and ET-1 measurement
Androgen-independent human prostate cancer cell lines DU-145,
PC-3, and JCA-1 (Muraki et al, 1990) and androgen-dependent
LNCaP cell lines (Horoszewicz et al, 1983) were maintained in
RPMI-1640 medium with 7% heat-inactivated fetal calf serum
(FCS). These cell lines were also maintained instead with 7% heat-
inactivated FCS removed of steroids with charcoal stripping
(HyClone Lab, Inc, Logan, UT, USA) to avoid possible inter-
ference in cell growth. Some of these cells were co-cultured with
devitalized bovine cortical bone slices pre-wetted with RPMI-
1640 medium (Dempster et al, 1987). The bottom of the culture
vessels were covered with bone slices, 4.4 ´ 4.4 mm pieces were
placed in each of the flat bottom wells of the 96-well plates prior to
addition of cells. During the culture period aliquots of the super-
natants were collected for the measurement of ET-1 level by a
sandwich immunoassay (R and D System, Minneapolis, MN,
USA) for quantitation of human ET-1 in fluid samples.
Some cell cultures at 1.5 ´ 105 cells ml–1 in RPMI-1640 and 7%
charcoal-stripped FCS were exposed to purified prostate-specific
antigen (PSA) (Chemicon International, Inc, Temecula, CA, USA)
prepared in RPMI-1640 medium at various concentrations for 
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collected and assayed for ET-1 levels by ELISA.
RT-PCR and Northern blot analysis
Total RNAs were extracted from prostate cancer cells with or
without exposure to bone slices for 1–2 days using a total RNA
isolation kit Ultraspec-II RNA (Biotech Lab Inc, Houston, TX,
USA). A Gene Amp RNA PCR Kit (Perkin Elmer, Foster City,
CA, USA) was employed for reverse transcription using oligo dT
and AMV reverse transcriptase. The cDNAs were used as
templates for PCR amplification. The amplification was
performed with 35 cycles of 1 min denaturing at 94°C, 1 min
annealing at 54°C, and 1 min elongation at 72°C. The specific
primers for ET-1 are sense 5¢-TTA AAG GGC ACT TGG GCT
GA-3¢, antisense 5¢-AAG ATG ATT TGA CGC TGT TT-3¢, repre-
senting positions 202–222/885–905 of endothelin-1 sequence
(Genbank: accession S56805). The expected size of PCR products
is 703 bp (Nelson et al, 1995). The primers for actin are 5¢CCT
CGC CTT TGC CGA TCC-3¢, antisense 5¢-GGA TCT TCA TGA
GGT AGT CAG TC-3¢. The predicted amplicon is 626 bp (Raff
et al, 1997). The presence of the PCR product was ascertained by
electrophoresis on 7.5% PAGE after staining with ethidium
bromide.
Electrophoresis and hybridization of Northern blot analyses
were performed by standard procedures. Blots were washed twice
at 65°C in 2 ´ SSC and 0.1% SDS for 15 min, followed by detec-
tion of autoradiography. Probes for ET-1 were labelled with g32P-
dCTP. The amount of RNA loaded was monitored with 28 S and
18 S ribosomal RNA stained by ethidium bromide.
Cell proliferation
Prostate cancer cell lines at 1.5 ´ 105 cells ml–1 in RPMI-1640
medium with 7% charcoal-stripped FCS were exposed to synthetic
ET-1 prepared in RPMI-1640 medium at various concentrations.
During the culture period, each culture was labelled with
2 mCi ml–1 of [3H]thymidine followed with trypsination and
scintillation counting (Abolhassani and Chiao, 1995). At least
triplicate experiments were performed for each data point and the
mean count per minute was presented.
Bone resorption assay
Bone resorption was quantified using the disaggregated osteoclast
resorption assay originated by Boyde et al (1984) and Chambers et
al (1984) and performed as described by Dempster et al (1987).
Briefly, osteoclasts were isolated from the long bones of neonatal
rats onto devitalized 4.4 ´ 4.4 mm bovine cortical bone slices pre-
wetted with medium 199 + Hanks’ salts. The slices were rinsed
to remove non-adherent cells and transferred to medium 199
containing Earle’s salts, sodium bicarbonate and 10% heat-inacti-
vated FCS containing vehicle alone or ET-1 prepared in the same
medium. Some bone-resorption cultures were added with prostate
cancer cell lines prepared in the same medium 199 approximately
18 h prior to the addition of isolated osteoclasts. Some of these
cultures were further supplemented with a rabbit antiserum with
specificity against human ET-1 (Abbott Laboratories, Abbott City,
IL, USA) at a final dilution of 1:1000. The antiserum supple-
mented alone in the culture was employed as a control.
After incubation the bone slices were fixed and stained for
tartrate-resistant acid phosphatase. The number of multinucleated
osteoclasts were counted on 12 replicate slices per treatment. Cells
were stripped from the slices by sonication in 0.25 M NH4OH, and
the number of resorption pits counted in the light microscope on
12 replicates per treatment after staining in toluidine blue.
Osteoclast viability was determined using the trypan blue exclu-
sion method.
Statistical analysis
A repeated measures analysis of variance was used to estimate the
within-subject effect of treatment (SAS Proc GLM, SAS Institute,
Cary, NC, USA). Preplanned contrasts compared the effect of each
treatment to the control and used a type I Bonferonni correction;
comparison-wise error rate was used to maintain an overall error
rate of 5%.
RESULTS
ET-1 increases after bone stimulation
The quantity of ET-1 in culture supernatants of prostate cancer cell
lines with or without co-culture with devitalized bovine bone
slices was determined by an ELISA procedure. Figure 1 shows that
ET-1 could be detected in the supernatant from unstimulated
cultures without bone slices. The culture media used as back-
ground lacked ET-1. After co-culturing with bone slices, there was
a significant increase of ET-1 in prostate cancer cell lines (Figure
1). ET-1 increase could be detected as early as 6 h after the initia-
tion of cultures. The magnitude of the ET-1 enhancement varied
among cell lines. ET-1 from androgen-independent cells DU-145,
PC-3 or JCA-1 increased from a mean of 4, 3 or 5 pg ml–1 to 8, 6 or
7 pg ml–1 per 105 cells by 24 h; respectively, representing approxi-
mately 40–100% increases (Figure 1). The androgen-dependent
LNCaP cells had a near background level of ET-1 without bone
culturing and the increase of ET-1 after exposure to bone was rela-
tively minor. LNCaP cells maintained in either regular FCS or in
steroid-depleted FCS showed no difference in this regard. Culture
supernatant from bone slices without cells was used as a back-
ground control, which had no detectable ET-1. These results
suggest that an increase of ET-1 quantity was the result of stimula-
tion by bone.
By RT-PCR amplification and Northern RNA blot analysis a
significantly enhanced level of ET-1 mRNA was detected with
these prostate cancer cell lines after co-culturing with bone slices,
as compared to those without bone. Figure 2 shows the increase by
RT-PCR with representative cell line DU-145. An autoradiograph
of Northern blot analysis is shown in Figure 2B, revealing an
expected 2.3 kb band (Bagnato et al, 1999), demonstrating the
presence of ET-1 mRNA in untreated cells and the increase after
bone exposure.
Inhibition of osteoclast bone resorption
Cells from human prostate cancer cell lines were added to bone
resorption cultures containing isolated osteoclasts, to evaluate
their effect on osteoclastic bone resorption. The presence of
androgen-independent PC-3, JCA-1 or DU-145 cells but not
androgen-dependent LNCaP cells caused significant (P < 0.05)
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bone resorption, as indicated by the number of resorption pits per
bone slice, could be achieved with DU-145 cells used at 105 cells
ml–1. This condition for mid-point inhibition was chosen for
subsequent analyses with a specific anti-human ET-1 antibody.
The addition of the antibody with DU-145 cells quantitatively
negated the DU-145-mediated inhibition (Figure 3A). A non-
specific Ig preparation used as a control showed no effect. The
antibody was also added to bone resorption cultures with LNCaP
cells but showed no effect, since LNCaP cells did not have an
significant effect on bone resorption (Figure 4A). The antibody
used alone in osteoclast cultures as a control also had no effect
(Figure 3A). There was no evidence of a lytic effect on osteoclasts
by any of the cell lines or in the antibody studies; the number of
osteoclasts per slice at the end of the experiments remained
unchanged from control values (Figures 3B and 4B). Other
controls include the addition of prostate cancer cells to bone
resorption cultures without osteoclasts, which showed no bone
resorption, and the exposure of prostatic cells to the antibody,
which revealed no cytolysis.
Figure 3A shows further that exposure to synthetic ET-1 at
10 nM could inhibit approximately 50% bone resorption,
duplicating the effect of DU-145 cells.
Supplementation of ET-1 together with the anti-ET-1 anti-
body completely blocked ET-1 activity (Figures 3A and 4A),
indicating a direct ET-1 activity on osteoclasts. Figure 3A also
shows that the combination of DU-145 and ET-1 used in the
bone resorption assay achieved a level of inhibition which was
slightly more than either used separately. There was no evidence
of a toxic effect of ET-1; the number of osteoclasts per slice at
the end of the experiments remained unchanged from control
values (Figures 3B and 4B). Additionally, the proportion of
osteoclasts excluding trypan blue was the same in the presence
or absence of ET-1. These results suggest that ET-1 derived
from DU-145 cells represents the major factor responsible for
modulating the osteoclastic bone resorption. In contrast,
androgen-dependent LNCaP cells may not have a sufficient
quantity of ET-1 to affect the osteoclastic function.
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Figure 2 Northern blot analysis (A) and RT-PCR amplification (B) show
increased expression of ET-1 in prostate cancer cells induced by bone. Left
lane in (A) Northern blot analysis indicates ET-1 from untreated prostate
cancer cells DU-145 cells at 2.3 kb position while right lane ET-1 from cells
co-cultured with bone slices. DU-145 cells were cultured with or without bone
for 1 day. Lanes 1 and 2 (B) are 703 bp RT-PCR products of ET-1 and lanes
3 and 4 are 626 bp RT-PCR products of control gene actin. Lanes 1 and 3
are from untreated DU-145 and lanes 2 and 4 are cells co-cultured with bone
slices for 1 day. MW is molecular weight marker of l DNA digested by Hind
III and EcoRI.
Figure 3 Effect of human androgen-independent prostate cancer cell line
DU-145 (1 ´ 105 cells ml–1) or synthetic ET-1 (10 nM) on bone resorption (A)
and on isolated rat osteoclasts (B). Control indicates resorption by isolated
osteoclasts in medium 199. Horizontal bar values are means ± SEM.
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Figure 1 Quantification of ET-1 (pg ml–1) in the culture supernatants from
human prostate cancer cell lines co-cultured with (black) or without (white)
devitalized bovine bone slices by ELISA. Aliquots of 1-day culture
supernatants were collected for the measurement. Graphs recorded the ET-1
quantities per 1.5 ´ 105 cells of androgen-independent prostate cell lines DU-
145, PC-3, JCA-1 and androgen-dependent LNCaP cells. Each cell line was
maintained in medium RPMI-1640 with 7% charcoal-stripped FCS. No ET-1
was detected in culture media or bone slice conditioned medium, negative
controls. Vertical bars indicate median values ± SEM.PSA stimulates ET-1 production
The effect of PSA on the production of ET-1 from prostatic cells
was analysed. Prostate cell lines were supplemented with purified
PSA at various concentrations and the ET-1 quantity in the 
culture supernatant was determined by ELISA. Medium controls
containing PSA at the same concentrations showed no detectable
ET-1. Figure 5 shows a PSA dose-related stimulatory effect on
ET-1 production that was detected for DU-145, PC-3, JCA-1 and
LNCaP cells. At PSA concentrations of 2.5–20 mg ml–1, a graduate
elevation of ET-1 with a maximum increase of 50% was detected
for JCA-1, PC-3 and DU-145 cells. For LNCaP cells, the stimula-
tory effect for ET-1 production was only found at a higher dose of
20 mg ml–1 PSA but not at lower dosages (Figure 5).
ET-1 stimulates DNA synthesis
Experiments were performed to determine the modulating effect of
ET-1 on the proliferation of prostate cancer cells. Each cell line in
steroid-depleted FCS medium was supplemented with exogenous
ET-1 at various concentrations and proliferation was assayed with
[3H]thymidine incorporation. ET-1 has a time- and dose- depen-
dent effect on the increase of DNA synthesis of prostate cancer
cells within a dose range of 1 ´ 10–12–1 ´ 10–7 M. A moderate stim-
ulatory effect was consistently observed after 1-day incubation.
Figure 6 shows the maximum activity seen with various ET-1
dosages such that approximately 32%, 29% and 25% increase of
DNA synthesis was observed with DU-145, JCA-1 and PC-3 cells,
respectively. In contrast to these androgen-independent cells,
androgen-dependent LNCaP cells had an approximately 10–16%
reduction of DNA synthesis after a 1-day exposure to ET-1, and
enhancement of approximately 62% after 2 days (Figure 6).
DISCUSSION
Utilizing a co-culture method consisting of prostate cancer cells
and bone slices, this report demonstrated that human prostate
cancer cells produce increased quantities of ET-1 after contacting
bone. The increase of ET-1 in the cultures was determined with an
ELISA procedure, while the elevation of mRNA level was shown
by RT-PCR and Northern blot analysis. The association of prostate
cancer cell-derived ET-1 with bone resorption was clarified.
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Figure 4 Effect of human androgen-dependent prostate cancer cells
LNCaP cells (1 ´ 105 cells ml–1) on bone resorption (A) and on isolated rat
osteoclasts (B). Synthetic ET-1 used at 10 nM was used as a positive control
of inhibition of bone resorption. Resorption by isolated osteoclasts in medium
199 was used as a control. Horizontal bar values are means ± SEM.
Figure 6 Stimulating effect of ET-1 on proliferation of human prostate
cancer cell lines as determined by [3H]thymidine incorporation. Graph shows
maximum enhancement of proliferation of DU-145, JCA-1, and PC-3 cells
after 1 day ET-1 exposure, and LNCaP cells after 2 days. Horizontal bars
represent means ± SEM of three experiments.
Figure 5 Stimulating effect of PSA on ET-1 production from human prostate
cancer cell lines maintained in RPMI-1640 with 7% charcoal-stripped FCS for
2 days. Graphs recorded the ET-1 quantities in the culture supernatants from
PC-3 (A), JCA-1 (B), DU-145 (C), and LNCaP cells (D) as detected by
ELISA. Vertical bars indicate means ± SEM.
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Thymidine incorporation (cpm ´ 1000)Osteoclastic bone resorption was inhibited by the presence of
prostate cancer cells to a degree similar to inhibition by ET-1. The
inhibition could be neutralized with a specific anti-ET-1 antibody.
The degree of antibody blocking was nearly complete, suggesting
that ET-1 is the major factor from prostate cancer cells responsible
for the inhibition of osteoclastic bone resorption. The antibody
most likely neutralized ET-1 after its release from cells, as we have
reported previously (Moonga and Chiao, 1998) that the activity
inhibiting osteoclastic bone resorption from prostate cancer cells
was secreted to the supernatants before interacting with osteo-
clasts. ET-1 from bone marrow cells as a regulator for osteoclasts
was previously reported (Towhidul et al, 1992), but no reference
was made linking this ET-1 function with prostate cancer cells.
Our experimental results support the interpretation that prostate
cancer cells in bone are induced to produce more ET-1 which stim-
ulates osteoblasts and also regulates osteoclast function. The up-
regulated ET-1 could disrupt the balance of bone remodelling. The
direction of the abnormal bone remodelling, such as increased
bone formation and resorption, may further depend on the balance
of ET-1 activity on osteoblasts and osteoclasts. It is conceivable
that other cytokines in bone regulation are important in this regard
as well, and could also influence the ET-1 activity. The expression
of these cytokine genes could be similarly affected by the cancer
cells and ET-1. However, this needs to be defined. The combined
effects of the altered genes and cytokine activities are therefore
postulated as a mechanism in the bone damage.
Compared to the androgen-independent prostate cancer cell
lines, androgen-dependent LNCaP cells do not have a significant
effect on bone resorption. LNCaP cells whether unstimulated or
exposed to bone had a level of ET-1 which was comparatively
lower than the other cell lines on a per-cell basis. ET-1 in LNCaP
cells can only be stimulated with PSA using much higher quanti-
ties than for androgen-independent cancer cells. These results
indicate that LNCaP cells may not actively produce ET-1 as a
major contributor affecting bone remodelling. Whether androgen-
unresponsive prostate cancer cells represent the prime cell type
causing osteoblastic bone lesions, and whether androgen-
responsive cells are only involved in the presence of highly
elevated PSA, is currently being investigated.
In addition to stimulation by bone, ET-1 levels in prostate
cancer cells could also be elevated by exposure to PSA in a dose-
dependent manner. This finding reveals a regulatory activity of
PSA which has not been previously described. PSA has been
reported to have a direct stimulatory effect on the proliferation of
prostate cancer cells (Wang et al, 1996). This finding suggests that
PSA enhances ET-1 production, with ET-1 subsequently stimu-
lating cell proliferation. The observation supports the hypothesis
that when prostate cancer cells metastasize to bone, they are stim-
ulated by bone to produce more ET-1, which in combination with
ET-1 from endothelial cells in bone marrow provides stimulation
for the growth of tumour cells (Figure 7). The cancer cells in turn
provide more ET-1 and PSA, promoting their own proliferation
and also affecting the activities of osteoblasts and osteoclasts and
hence bone remodeling. Figure 7 illustrates the role of ET-1 and
PSA in perpetuating the interactions between cancer and bone
cells to cause cancer growth and bone damage.
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